PMID- 37048814
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230415
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 12
IP  - 7
DP  - 2023 Apr 6
TI  - Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses 
      on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic 
      Leukemia.
LID - 10.3390/jcm12072731 [doi]
LID - 2731
AB  - Tumor growth and metastasis are reliant on intricate interactions between the 
      host immune system and various counter-regulatory immune escape mechanisms 
      employed by the tumor. Tumors can resist immune surveillance by modifying the 
      expression of human leukocyte antigen (HLA) molecules, which results in the 
      impaired presentation of tumor-associated antigens, subsequently evading 
      detection and destruction by the immune system. The management of chronic 
      lymphocytic leukemia (CLL) is based on symptom severity and includes various 
      types of targeted therapies, including rituximab, obinutuzumab, ibrutinib, 
      acalabrutinib, zanubrutinib, idelalisib, and venetoclax. These therapies rely on 
      the recognition of specific peptides presented by HLAs on the surface of tumor 
      cells by T cells, leading to an immune response. HLA class I molecules are found 
      in most human cell types and interact with T-cell receptors (TCRs) to activate T 
      cells, which play a vital role in inducing adaptive immune responses. However, 
      tumor cells may evade T-cell attack by downregulating HLA expression, limiting 
      the efficacy of HLA-dependent immunotherapy. The prognosis of CLL largely depends 
      on the presence or absence of genetic abnormalities, such as del(17p), TP53 point 
      mutations, and IGHV somatic hypermutation status. These oral targeted therapies 
      alone or in combination with anti-CD20 antibodies have replaced 
      chemoimmunotherapy as the primary treatment for CLL. In this review, we summarize 
      the current clinical evidence on the impact of HLA- and cytokine-type responses 
      on outcomes after targeted therapies currently used to treat CLL.
FAU - Andreescu, Mihaela
AU  - Andreescu M
AUID- ORCID: 0000-0003-0532-7929
AD  - Department of Clinical Sciences, Hematology, Faculty of Medicine, Titu Maiorescu 
      University of Bucharest, 040051 Bucharest, Romania.
AD  - Department of Hematology, Colentina Clinical Hospital, 020125 Bucharest, Romania.
FAU - Berbec, Nicoleta
AU  - Berbec N
AD  - Department of Hematology, Coltea Clinical Hospital, 020125 Bucharest, Romania.
AD  - Faculty of Medicine, Carol Davila University of Bucharest, 040051 Bucharest, 
      Romania.
FAU - Tanase, Alina Daniela
AU  - Tanase AD
AUID- ORCID: 0000-0003-3075-499X
AD  - Faculty of Medicine, Carol Davila University of Bucharest, 040051 Bucharest, 
      Romania.
AD  - Department of Hematology, Fundeni Clinical Hospital, 020125 Bucharest, Romania.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230406
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC10094967
OTO - NOTNLM
OT  - BTK inhibitors
OT  - chronic lymphocytic leukemia
OT  - natural killer cells
OT  - treatment strategy
OT  - tumor
COIS- The authors declare no conflict of interest.
EDAT- 2023/04/14 06:00
MHDA- 2023/04/14 06:01
PMCR- 2023/04/06
CRDT- 2023/04/13 01:20
PHST- 2023/03/02 00:00 [received]
PHST- 2023/04/02 00:00 [revised]
PHST- 2023/04/04 00:00 [accepted]
PHST- 2023/04/14 06:01 [medline]
PHST- 2023/04/13 01:20 [entrez]
PHST- 2023/04/14 06:00 [pubmed]
PHST- 2023/04/06 00:00 [pmc-release]
AID - jcm12072731 [pii]
AID - jcm-12-02731 [pii]
AID - 10.3390/jcm12072731 [doi]
PST - epublish
SO  - J Clin Med. 2023 Apr 6;12(7):2731. doi: 10.3390/jcm12072731.